SUPN Q2 2018 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q2 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$100M+31.3% YoY

Gross Profit

$96M96.3% margin

Operating Income

$36M35.9% margin

Net Income

$31M30.9% margin

EPS (Diluted)

$0.57

QoQ Revenue Growth

+10.1%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$6M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$853M

Total Liabilities

$462M

Stockholders' Equity

$390M

Cash & Equivalents

$35M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$100M	$76M	+31.3%
Gross Profit	$96M	$72M	+33.2%
Operating Income	$36M	$26M	+37.0%
Net Income	$31M	$17M	+77.0%

Revenue Segments

Product

$97M49%

Trokendi X R

$76M39%

Oxtellar X R

$21M10%

Royalty

$2M1%

License

$750,0000%